Navigating the Changing Landscape of Relapsed/Refractory Multiple Myeloma: Optimizing Treatment Strategies

home / frontline-forum / navigating-the-changing-landscape-of-relapsed-refractory-multiple-myeloma-optimizing-treatment

Samer Al-Hadidi, MD, MS, FACP, and Leo Shunyakov, MD, discuss their approaches to dosing talquetamab and treating CNS metastases in patients with relapsed/refractory multiple myeloma, sharing clinical experiences and addressing treatment challenges.

EP. 1: R/R MM: Treating Patients with CNS Metastases Involvement

Samer Al-Hadidi, MD, MS, FACP;Leo Shunyakov, MD

November 22nd 2024

Panelists discuss how they approach treatment strategies and challenges for relapsed/refractory multiple myeloma patients with CNS involvement, sharing case details and preferences among available therapeutic options.

EP. 2: Optimal Dosing Strategies and Managing AEs

Samer Al-Hadidi, MD, MS, FACP;Leo Shunyakov, MD

November 22nd 2024

Panelists discuss how they dose talquetamab in clinical practice, comparing its administration schedule to other bispecific antibodies and addressing dosing-related challenges they encounter.

EP. 3: R/R MM: Bispecifics in R/R MM: Key Takeaways

Samer Al-Hadidi, MD, MS, FACP;Leo Shunyakov, MD

November 22nd 2024

Panelists discuss how to manage talquetamab-associated adverse events, such as skin toxicities and dysgeusia, sharing their clinical experience with toxicity timing, frequency, and key strategies for fellow oncologists implementing bispecific antibodies in relapsed/refractory multiple myeloma.